China-Administration of Nicorandil Group(CHANGE)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.
Also called NCT03445728
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 238 participants
- Sponsor
- Registry
-
NCT03445728
-
- Other papers using this trial's data
- Effects of Nicorandil Administration on Infarct Size in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03445728. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-24 (actual); primary completion 2020-07-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- China-Administration of Nicorandil Group(CHANGE)
- Condition
- Myocardial Infarction
- Condition
- Percutaneous Coronary Intervention
- Condition
- Nicorandil
- Intervention (Drug)
- Nicorandil
- Intervention (Other)
- Placebo
- Lead sponsor
- Chinese PLA General Hospital
- Collaborator
- First People's Hospital of Yulin
- Collaborator
- Beijing Chao Yang Hospital
- Collaborator
- Wuhan Asia Heart Hospital
- Collaborator
- Hainan General Hospital
- Collaborator
- Zunyi Medical College
- Collaborator
- Guizhou Provincial People's Hospital
- Collaborator
- Second Affiliated Hospital of Nanchang University
- Collaborator
- The Second Hospital of Hebei Medical University
Record details
- Record id
cardio:ct-nct03445728- Content hash
cd40c242fb2e09b9ac27aba10e44f60f4574b0f19c21b07031e2ca17fd46b3ba